VEGF Inhibitors in Brain Tumors

Priscilla K. Brastianos, MD, and Tracy T. Batchelor, MD, MPH

Abstract: Glioblastomas are highly vascular tumors. Recent preclinical and clinical investigations have demonstrated that agents targeting angiogenesis may have efficacy in this type of tumor. Antibodies to vascular endothelial growth factor (VEGF), VEGF receptor tyrosine kinase inhibitors, immunomodulatory agents, and soluble decoy VEGF receptors are being studied in this patient population. Unfortunately, treatment inevitably fails. Further studies are needed to understand mechanisms of tumor resistance and to identify other therapeutic targets that mediate angiogenesis.

Introduction

The prognosis of patients with malignant brain tumors is poor despite advances in chemotherapy, surgery, and radiotherapy. Gliomas account for more than two-thirds of all brain tumors, with glioblastomas being the most frequent and malignant histologic glioma subtype.1,2 The 5-year survival rate of patients with glioblastomas is less than 3%.2 The outlook for patients with metastatic disease to the brain is also poor, with median survival times ranging from several months to a few years, depending on the age and performance status of the patient, the tumor type, and the extent of metastatic disease.3 It is apparent that new treatment modalities are desperately needed.

In 1971, Judah Folkman proposed that angiogenesis, the formation of new blood vessels, is an important mechanism by which tumor growth occurs.4 Though this idea was initially met with resistance, extensive investigation over the last 3 decades has demonstrated the critical role of angiogenesis in the growth of solid tumors.5,6 Thirty-eight years after Dr. Folkman proposed his idea, there are 3 drugs approved by the U.S. Food and Drug Administration (FDA) that target angiogenesis. Bevacizumab (Avastin, Genentech), a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), is approved in combination with standard chemotherapy as first-line therapy for the treatment of non-small cell lung cancer, breast cancer, advanced colorectal cancer, and metastatic renal cell carcinoma. Bevacizumab has also received accelerated approval as monotherapy for recurrent glioblastoma.7,8 Sorafenib (Nexavar, Bayer), a multi-targeted (including VEGF) receptor kinase inhibitor, has been approved as a single agent in advanced renal cell and hepatocellular carcinoma.9,10 Sunitinib
BRASTIANOS AND BATCHELOR

(Sutent, Pfizer), also a multi-targeted (including VEGF) receptor kinase inhibitor, is approved for advanced renal cell carcinoma and gastrointestinal stromal tumors.12,13

In this review we will summarize the role of angiogenesis in malignant brain tumors and then outline the experimental anti-VEGF therapies being studied in brain tumors. We will focus on therapies that are in later stages of development. Both primary and metastatic brain tumors will be reviewed, though most of the published data are from studies of malignant gliomas.

Angiogenesis and Brain Tumors

Malignant gliomas are highly vascular tumors and, like all solid tumors, require angiogenesis for their growth.14 A distinct histopathologic feature of glioblastoma is microvascular proliferation.15 The vasculature of glioblastomas is highly tortuous and disorganized, with abnormalities in vessel pericyte coverage, and basement membrane thickness.15,20 The permeability of these vessels is increased, with the degree of permeability varying in a heterogeneous way, both temporally and spatially.20,22 This abnormal permeability and morphologically aberrant vascular network are associated with abnormal blood flow and heterogeneous delivery of oxygen, nutrients, and systemically administered drugs.23 The tumor microenvironment created is characterized by areas of hypoxia, interstitial hypertension, and necrosis.24,28 As tumors grow beyond a diameter of 1–2 mm, the integrity of the blood brain barrier is disrupted both functionally and structurally.20 The abnormal leakage and resultant contrast enhancement seen on computed tomography and magnetic resonance imaging scans of patients with glioblastomas is a result of this blood brain barrier disruption.

Glioblastomas utilize several mechanisms to form new vasculature (Figure 1). Initially tumor growth may occur by “co-option” of pre-existing, native blood vessels. Malignant cells migrate along normal blood vessels, structurally destabilizing them. This causes regression of these vessels, with decreased perfusion and local hypoxia.29 The hypoxia triggers the secretion of several growth factors such as vascular endothelial growth factor (VEGF), stromal-cell-derived factor (SDF-1), basic fibroblast growth factor (bFGF), and Interleukin 8 (IL8).30,31 New vasculature may also form via vasculogenesis, whereby bone marrow–derived progenitor cells enter the circulation and are directly incorporated into vessels.32

A number of complex and redundant molecular pathways drive angiogenesis. As tumor angiogenesis has

Figure 1. Schematic representation of different mechanisms of new blood vessel formation. A) Blood vessels are composed of astrocytes, pericytes, and endothelial cells. B) Tumor cells infiltrate along blood vessels. C) As the tumor grows, it co-ops normal capillaries using various cytokines. D) Blood vessels are compressed and destabilized, which decreases perfusion, and results in hypoxia. Hypoxic conditions result in increased secretion of several growth factors such as vascular endothelial growth factor (VEGF), stromal-cell-derived factor (SDF-1), basic fibroblast growth factor (bFGF), and Interleukin 8 (IL8). E) Bone-marrow-derived (BMD) cells and SDF-1 are recruited to induce vasculogenesis.

been reviewed in detail elsewhere, we will briefly summarize key features and focus our attention on the VEGF signaling axis. Glioblastomas produce several pro-angiogenic factors, which include VEGF, platelet-derived growth factor (PDGF), hepatocyte growth factor/scatter factor (HGF/SF), and basic fibroblast growth factor (bFGF). VEGF-A (also referred to as VEGF), one of the key regulators of tumor angiogenesis, transduces its signal primarily through VEGF-receptor 2 (VEGFR-2), which is primarily located on the endothelial cell surface. VEGF expression may be increased by several factors. Hypoxic conditions increase expression and stabilize heterodimeric transcription factor HIF-1, which is a key mediator of the cellular response to hypoxia, by inducing transcription of many genes involved in cell survival and angiogenesis, including VEGF. Higher levels of HIF-1 and VEGF are associated with higher tumor grades.

VEGF expression is also increased by nitric oxide, acidosis, other growth factors (e.g., basic fibroblast growth factor, stem cell factor, epidermal growth factor, scatter factor/hepatocyte growth factor), loss of certain tumor suppression genes (e.g., p53), and activation of oncogenes (e.g., v-src). The binding of VEGF to VEGFR-2, with subsequent dimerization of the receptor, results in a cascade of intracellular molecular events culminating in endothelial cell proliferation, migration, and survival. These pathways include the mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3'-kinase (PI3K)-Akt pathways. VEGF also upregulates Notch Delta-like-ligand 4 (Dll4) expression. The Notch Dll pathway is an important stimulator of angiogenesis and is currently under investigation as a potential therapeutic target. Inhibition of Dll4 promotes nonproductive angiogenesis, resulting in increased hypoxia, poor perfusion, and decreased tumor growth.

VEGF also interacts with the angiopoietin pathway. Angiopoietin-1 (ang-1) and angiopoietin-2 (ang-2), an agonist/antagonist pair with significant sequence homology, are the major ligands that bind to and mediate signaling by Tie-2, a tyrosine kinase receptor expressed on endothelial cells. In the presence of VEGF, the binding of ang-2 to Tie-2 promotes angiogenesis. In preclinical animal models of angiogenesis, ang-2 inhibition prevented VEGF-stimulated neovascularization. Further understanding of these pathways may enable the development of novel therapeutic agents.

**Mechanism of Action of VEGF Inhibitors in Brain Tumors**

The mechanism of action of anti-VEGF agents has not been completely elucidated, though several hypotheses have been suggested. Classically, VEGF inhibitors have been thought to work by preventing new blood vessel growth, which deprives the tumor of oxygen and nutrients. A second potential mechanism of action is vascular normalization (Figure 2). According to this hypothesis, VEGF inhibitors may transiently normalize the tumor vascular network by ‘pruning’ immature vessels and improving their coverage with perivascular cells and basement membrane. This vascular normalization may improve the delivery of concurrent chemotherapeutic agents and enhance response to ionizing radiation.

In mouse models of glioblastoma, VEGFR-2 inhibition produced a time window of reduced tumor hypoxia during which radiation had a synergistic effect with anti-VEGFR-2 therapy. During this normalization window, pericytes are recruited to blood vessels by activation of ang-1/Tie2 signaling. These vessels are more efficient at oxygen delivery, thus augmenting the effects of radiation.

Finally, VEGF inhibitors may disrupt the interaction between endothelial cells and glioblastoma “stem-like” cells, which are the self-renewing cells that may give rise to gliomas. Disruption of the perivascular-stem cell niche may contribute to the death of these stem cells. Many anti-angiogenic agents, based on these proposed mechanisms of action, are currently under investigation for the treatment of brain tumors.

**VEGF Antibodies**

**Bevacizumab**

Bevacizumab is a recombinant humanized monoclonal antibody that neutralizes all isoforms of human VEGF. Thirty-three years after the concept of angiogenesis was introduced by Dr. Folkman, bevacizumab became the first drug that was developed as an angiogenesis inhibitor to be approved by the FDA. Several studies have demonstrated that bevacizumab may have activity against recurrent malignant gliomas. In case series of patients with recurrent malignant glioma treated with the combination of bevacizumab and conventional chemotherapy, radiographic response proportions ranging from 27–66% have been reported. In a study of 55 patients with recurrent glioblastoma, a 6-month progression-free survival (PFS) rate of 42% was observed, which compares favorably to historical databases in this patient population, in which median 6-month PFS rates were 9–15%. An anti-edema effect was also noted in these studies, with a reduction in corticosteroid requirements in approximately one-third of patients. Bevacizumab was generally well-tolerated in these studies, with the most frequent complications being hemorrhagic and thromboembolic events. In a retrospective series of 77 patients treated with bevacizumab and irinotecan, complications included 5 intratumoral
hemorrhages, 7 thromboembolic events, and 1 reversible leukoencephalopathy.58 These promising results lead to the first prospective phase II trial of irinotecan and bevacizumab in recurrent grade III-IV gliomas, in which 68 patients were treated on 2 schedules. The radiographic response rate was 57% in glioblastoma patients. Clinical improvement was reported, along with a decrease in steroid requirements. The 6-month PFS rate was 43% in glioblastoma patients. Toxicities were similar to those reported in prior studies, and included 2 intracranial hemorrhages (3%) and 8 thromboembolic events (12%).61-63 Similar promising results have been reported in subsequent prospective studies assessing the combination of bevacizumab and irinotecan.64 In a phase II trial of 48 heavily pretreated patients with recurrent glioblastoma, patients were treated with bevacizumab initially, and with the combination of irinotecan and bevacizumab after tumor progression. The 6-month PFS rate was 29%, and median overall survival was 31 weeks.65 In a noncomparative, randomized phase II study, 167 patients with recurrent glioblastoma were randomly assigned to receive bevacizumab with or without irinotecan.66 The 6-month PFS rate was 50% in the combination therapy arm and 35% in the bevacizumab arm. The majority of patients had at least a 50% reduction in their corticosteroid dose. Median survival was 8.9 months in the combination arm and 9.7 months in the bevacizumab-alone arm.66 Patients receiving the combination therapy had a higher rate of grade 3 toxicities than those receiving bevacizumab alone (67% vs 48%). Further studies are warranted to investigate whether the addition of irinotecan confers a significant advantage when compared to bevacizumab alone.

Based on the results of these trials, bevacizumab has been approved for use as a single agent in recurrent glioblastoma. A number of trials are now underway to evaluate the efficacy of bevacizumab in combination with other agents for patients with recurrent, as well as newly diagnosed, glioblastoma.

**VEGF-Trap**

Aflibercept (VEGF-Trap, Regeneron) is a potent, high-affinity, soluble decoy VEGF receptor fused to an immunoglobulin constant region that inhibits tumor growth when studied in preclinical glioma models.67,68 Preliminary data from a single-arm, phase II trial of aflibercept in patients with recurrent malignant glioma demonstrated response proportions of 30% in glioblastoma and 50% in grade III gliomas. However, there was treatment-related discontinuation of therapy in 25% of patients because of

---

**Figure 2.** Schematic representation of mechanisms of anti-angiogenic treatment. A) Healthy tissues have balanced signaling from pro- and anti-angiogenic factors, and this results in an organized, effective vasculature. B) Tumors produce anti-angiogenic factors, which create a highly disorganized vascular network. C) Anti-angiogenic therapy can normalize the vasculature and allows for more effective delivery of drug. D) With potent anti-angiogenesis, the tumor is starved of nutrients and oxygen, with resulting necrosis of tumor.

IFP=interstitial fluid pressure; pO2=tissue oxygen level

tyrcoxicity. There are ongoing trials of aflibercept in combination with radiation and temozolomide in newly diagnosed glioblastoma and in recurrent malignant glioma.

**Tyrosine Kinase Inhibitors**

**Cediranib**
Cediranib (Recentin, AstraZeneca) is a potent pan-VEGFR receptor tyrosine kinase receptor with additional activity against c-Kit and PDGF receptors. In a phase II study, recurrent glioblastoma patients were treated with cediranib monotherapy, with 17 of 30 patients achieving objective partial radiographic responses and a 6-month PFS proportion of 26%. The majority of patients had their steroid doses decreased or discontinued altogether after initiation of cediranib. Cediranib was generally well tolerated, with treatment-related discontinuation of therapy in 2 of 31 patients. Toxicities included diarrhea, fatigue, and hypertension. Notably, there were no intracranial hemorrhages observed. MRI techniques demonstrated reduction in tumor-associated edema and tumor vasculature normalization in patients receiving cediranib. A phase III study investigating the combination of cediranib and lomustine in recurrent glioblastoma is ongoing (Table 1).

**Vatalanib**
Vatalanib (PTK787, Novartis) is an oral pan-VEGFR, c-Kit, and PDGFR tyrosine kinase inhibitor that was investigated for the treatment of newly diagnosed and recurrent malignant gliomas. Preclinical models have shown that vatalanib halts VEGF-mediated glioma growth. When investigated as monotherapy in a phase I/II clinical trial of patients with recurrent glioblastoma, vatalanib produced radiographic responses in 4% of patients and stable disease in 56%. Dose-limiting toxicities included transaminitis, nausea/vomiting, cerebral edema, fatigue, and deep-vein thrombosis. A phase I study of vatalanib plus imatinib (Gleevec, Novartis) and hydroxyurea in recurrent malignant gliomas demonstrated that vatalanib doses of up to 1,000 mg twice/day were well tolerated. Dose-limiting toxicities were hematologic (cytopenias), renal, and gastrointestinal. Of note, no patients developed intracranial hemorrhages. Twenty-four percent of patients achieved a partial radiographic response and 49% of patients achieved disease stability.

**Other Tyrosine Kinase Inhibitors**
Sorafenib (Nexavar, Bayer) is a multitargeted kinase inhibitor with activity against many kinases including VEGFR, PDGFR, c-Kit, Ret, and Raf. Sorafenib has antiproliferative activity in vitro against malignant glioma cell lines. A phase I trial demonstrated that sorafenib is well-tolerated in patients with recurrent malignant glioma. Further studies with sorafenib are underway. Clinical studies using other VEGF receptor inhibitors, including sunitinib, AEE788 (Novartis), and vandetanib (ZD6474, AstraZeneca), are also ongoing (Table 1).

**Immunomodulatory Agents**

**Thalidomide and Lenalidomide**
Thalidomide (Thalomid, Celgene) has been investigated as a potential anti-angiogenic therapy in various cancers including gliomas and brain metastases. Thalidomide has potent anti-angiogenic activity in preclinical models. The immunomodulatory effects of thalidomide are believed to be mediated through the inhibition of tumor necrosis factor, but this mechanism is not thought to be responsible for its anti-angiogenic activity. The mechanism of action is unclear, but is possibly due to the inhibition of VEGF and bFGF. When thalidomide has been used as monotherapy in recurrent glioblastoma patients, results have been disappointing, with partial radiographic response proportions of only 5–6%. Combination therapies have also been studied. Thalidomide, when combined with temozolomide (Temodar, Schering-Plough), had little activity in recurrent gliomas. Adding thalidomide to the combination of temozolomide and radiation therapy in newly diagnosed glioblastoma patients also did not confer a survival advantage, nor did the combination of temozolomide, thalidomide, and celecoxib. However, the combination of carmustine and thalidomide was associated with a radiographic response proportion of 24% in a phase II trial, which compares favorably to historical controls. Lenalidomide (Revlimid, Celgene), a more potent thalidomide analog with greater antiangiogenic activity, did not appear to have efficacy in a phase I trial in combination with radiation in newly diagnosed glioblastoma patients. Activity was also limited when it was used as monotherapy in patients with recurrent malignant glioma.

In addition to being studied in glioma patients, thalidomide has also been evaluated in patients with brain metastases. In a phase III study, patients with multiple brain metastases were randomized to receive conventional whole-brain radiation therapy plus thalidomide versus whole-brain radiation therapy alone. Median survival in both groups was 3.9 months. Thalidomide was not well-tolerated, with discontinuation of therapy in 48% of patients secondary to side effects. A phase II study of thalidomide as a single agent in patients with metastatic melanoma to the brain demonstrated limited activity. The combination of thalidomide, temozolomide, and
Table 1. Select Anti-vascular Endothelial Growth Factor Agents Currently in Clinical Trials for Glioblastoma*

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mechanism</th>
<th>Trial Population</th>
<th>Phase</th>
<th>Combination</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aflibercept</td>
<td>VEGF-A,-B, placental growth factor “receptor decoy”</td>
<td>Recurrent GBM</td>
<td>II</td>
<td></td>
</tr>
<tr>
<td>Bevacizumab</td>
<td>VEGF-A antibody</td>
<td>Newly diagnosed GBM or gliosarcoma stable following RT and TMZ</td>
<td>II</td>
<td>BVB + erlotinib + TMZ</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Recurrent glioblastoma</td>
<td>II</td>
<td>Bevacizumab + temozolomide</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Newly diagnosed GBM</td>
<td>II</td>
<td>Concurrent RT, TMZ + BVB followed by BVB/everolimus</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Newly diagnosed GBM</td>
<td>II</td>
<td>BVB, irinotecan, RT vs BVB, TMZ, RT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Newly diagnosed GBM</td>
<td>III</td>
<td>TMZ + RT + BVB vs TMZ +RT</td>
</tr>
<tr>
<td><strong>VEGF receptor inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AEE788</td>
<td>VEGFR-1,2, EGFR inhibitor</td>
<td>Recurrent GBM</td>
<td>I/I</td>
<td>Everolimus</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Recurrent GBM</td>
<td>I/I</td>
<td></td>
</tr>
<tr>
<td>CT-322</td>
<td>VEGFR-1–3 inhibitor</td>
<td>Newly diagnosed GBM</td>
<td>I</td>
<td>RT + TMZ</td>
</tr>
<tr>
<td>Cediranib</td>
<td>VEGFR-1–3, PDGFR, c-kit inhibitor</td>
<td>Recurrent GBM</td>
<td>III</td>
<td>Versus lomustine</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>VEGFR-1–3, PDGFR, c-kit inhibitor</td>
<td>Recurrent GBM</td>
<td>II</td>
<td></td>
</tr>
<tr>
<td>Sorafenib</td>
<td>VEGFR-2,3, BRAF, PDGFR, c-Kit, Ras, p38 inhibitor</td>
<td>Newly diagnosed GBM or gliosarcoma</td>
<td>I/I</td>
<td>RT + TMZ</td>
</tr>
<tr>
<td></td>
<td>VEGFR-2, PDGFR, c-Kit, Flt3 inhibitor</td>
<td>Recurrent GBM</td>
<td>I/I</td>
<td>Erlotinib, tipifarnib or temsirolimus</td>
</tr>
<tr>
<td>Sunitinib</td>
<td>VEGFR-2, PDGFR, c-Kit, Flt3 inhibitor</td>
<td>Recurrent GBM</td>
<td>II</td>
<td></td>
</tr>
<tr>
<td>Vandetanib (ZD6474)</td>
<td>VEGFR-2, EGFR</td>
<td>Recurrent high-grade and progressive low-grade glioma</td>
<td>I/I</td>
<td>EIAEDs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Newly diagnosed GBM</td>
<td>I/I</td>
<td>TMZ + RT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Recurrent MG</td>
<td>I</td>
<td>Etoposide</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Recurrent MG</td>
<td>I</td>
<td>Imatinib and hydroxyurea</td>
</tr>
<tr>
<td>Vatalanib (PTK787)</td>
<td>VEGFR1–3,PDGFR, c-kit inhibitor</td>
<td>Newly diagnosed GBM</td>
<td>I</td>
<td>TMZ + RT + vatalanib in patients taking EIAEDs</td>
</tr>
<tr>
<td><strong>Immunomodulatory agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lenalidomide</td>
<td>Unknown</td>
<td>Recurrent GBM</td>
<td>I/I</td>
<td>Irinotecan</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>Unknown</td>
<td>Newly diagnosed GBM</td>
<td>II</td>
<td>RT followed by TMZ, thalidomide, celecoxib</td>
</tr>
</tbody>
</table>

*Please see the National Institutes of Health’s ClinicalTrials.gov website for information regarding ongoing trials (http://www.clinicaltrials.gov).

BVB=bevacizumab; EGFR=epithelial growth factor receptor; EIAEDs=enzyme-inducing anti-epileptic drugs; GBM=glioblastoma; MG=malignant gliomas; PDGFR=platelet-derived growth factor receptor; RT=radiation therapy; TMZ=temozolomide; VEGFR=vascular endothelial growth factor receptor.
whole-brain radiation therapy produced little efficacy in patients with central nervous system metastases from melanoma. Several clinical trials are underway to further investigate thalidomide and lenalidomide in malignant gliomas as well as in metastatic brain tumors.

**Anti-edema Effects**

Primary and metastatic brain tumors are often associated with a significant amount of vasogenic edema due to the highly permeable vessels formed within these tumors. Vasogenic brain edema is a primary reason why a large proportion of brain tumor patients require treatment, often long-term, with corticosteroids. Studies have demonstrated a decrease in vascular permeability in patients treated with anti-VEGF agents, specifically with cediranib, vatalanib, and bevacizumab. 

In a recent phase II study of cediranib in patients with recurrent glioblastoma, a reduction in tumor-associated edema was demonstrated with MRI. The effects of cediranib were also evaluated in 3 different orthotopic glioblastoma mouse models, which showed that cediranib significantly alleviated edema through rapid normalization of tumor vasculature. Of note, survival time was significantly prolonged with no change in tumor growth, indicating that a potent anti-edema effect may prolong survival in these particular orthotopic glioma models.

**Resistance to Anti-angiogenic Therapy**

Though anti-angiogenic agents are associated with clinical benefit, the effects are transitory at best. Most patients treated with anti-angiogenic agents eventually experience tumor progression. Evidence is emerging that tumors develop an adaptive response to angiogenesis inhibitors. Postulated mechanisms for this resistance include upregulation of alternative pro-angiogenic pathways, improved protection of tumor vasculature by increasing pericyte coverage, recruitment of vascular progenitor cells from the bone marrow, and enhanced ability of tumor cells to invade without angiogenesis. Furthermore, some tumors have a pre-existing, intrinsic resistance to anti-angiogenic agents via activation of redundant, VEGF-independent, pro-angiogenic pathways. This may explain why a substantial minority of patients in clinical trials fail to demonstrate even a minor response to anti-VEGF therapy. Further investigations are needed to understand both the adaptive and the pre-existing intrinsic pathways that enable a tumor to evade anti-angiogenic therapy.

**Monitoring Response to Anti-angiogenic Agents**

Conventionally, response to therapy has been assessed by monitoring the extent of contrast enhancement on CT and MRI scans. Glioblastomas enhance because contrast agents administered intravenously leak into the brain parenchyma in the setting of blood brain barrier dysfunction. Anti-VEGF agents decrease the permeability of the tumor vasculature, thereby reducing contrast leakage on post-contrast T1-weighted MRI scans. This makes interpretation of post-treatment images challenging. Alternative imaging sequences may be useful in the detection of progressive tumors in the setting of anti-VEGF therapy. Diffusion imaging is one such promising modality with areas of restricted diffusion possibly correlating with progressive, infiltrative tumor.

New radiographic response criteria are under development for the assessment of efficacy of anti-VEGF therapies in brain tumor patients.

**Conclusion**

Angiogenesis is a complex molecular process that is incompletely understood. Recent preclinical and clinical investigations have demonstrated that anti-VEGF agents, either alone or in combination with chemotherapy, may have efficacy in the treatment of malignant brain tumors. To date, these agents have been associated with prolonged PFS and reduction of vasogenic brain edema. Larger prospective trials are underway to validate these results and to assess the impact on patient survival. Unfortunately, in most patients, treatment inevitably fails. Further studies are needed to target other pro-angiogenic signaling pathways. New neuro-imaging techniques are essential to accurately assess tumor response to anti-VEGF therapy. Nevertheless, inhibition of angiogenesis is a promising therapeutic approach that has the potential to have a significant impact on the treatment of both metastatic and primary brain tumors.

**References**


(Continued on page 768)
(Continued from page 760)


